Increase walking endurance with exercise
- Trial ID
- NCT06339398
- Official Title
- Dose-response Effects of Physical Exercise Standardized Volume on Peripheral Biomarkers, Clinical Response and Brain Connectivity in Parkinson's Disease: a Prospective, Observational, Cohort Pilot Study
- Goal
- Increase walking endurance with exercise
- Status
- RECRUITING
- Sponsor
- Casa di Cura San Raffaele Cassino
- Study Type
- OBSERVATIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson Disease
- Interventions
- Aerobic exercise
Plain-Language Summary
The trial is testing whether different amounts of aerobic exercise change blood biomarkers, improve motor and clinical symptoms, and reshape brain connectivity in people with Parkinson's. Participants follow a standardized aerobic program that raises heart rate and cardiorespiratory fitness through walking or similar activity; increased fitness can boost neurotrophic factors like BDNF, lower inflammation, and alter brain network connectivity, and researchers will track blood tests, clinical scores, and brain imaging. Everyone stays on stable dopaminergic medication, so exercise is being studied as an add-on rather than a replacement. The study plans to enroll 30 people aged 30 to 80 with Parkinson's at Hoehn and Yahr stage II or III in the ON phase, who can do a 6-minute walk and have no serious heart, metabolic, cognitive, or musculoskeletal issues that make exercise unsafe.
Locations
- San Raffaele Cassino, Cassino, Frosinone, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Aerobic exercise. The trial is testing whether different amounts of aerobic exercise change blood biomarkers, improve motor and clinical symptoms, and reshape brain connectivity in people with Parkinson's. Participants follow a standardized aerobic program that raises heart rate and cardiorespiratory fitness through walking or similar activity; increased fitness can boost neurotrophic factors like BDNF, lower inflammation, and alter brain network connectivity, and researchers will track blood tests, clinical scores, and brain imaging. Everyone stays on stable dopaminergic medication, so exercise is being studied as an add-on rather than a replacement. The study plans to enroll 30 people aged 30 to 80 with Parkinson's at Hoehn and Yahr stage II or III in the ON phase, who can do a 6-minute walk and have no serious heart, metabolic, cognitive, or musculoskeletal issues that make exercise unsafe.
- Who can participate?
- Participants must be between 30 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 11 months.